Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2025-12-29 @ 12:03 PM
Study NCT ID:
NCT01326533
Status:
COMPLETED
Last Update Posted:
2016-02-26
First Post:
2011-03-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
Sponsor:
University of Pittsburgh
Organization:
Study Overview
Official Title:
Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.
Detailed Description:
Diabetes is approaching epidemic proportions in the United States. This study evaluates the mechanisms of action of a generic drug that may have effects on glucose metabolism.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 5R21DK082878-02 | NIH | None | https://reporter.nih.gov/quic… | View |